Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High Risk for Vascular Outcomes - ACCELERATE Trial

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High Risk for Vascular Outcomes - ACCELERATE Trial

By Cleveland Clinic Heart, Vascular and Thoracic Institute FEATURING Steven Nissen

825 views

July 26, 2016

Dr. Steve Nissen discusses the results and clinical implications of the ACCELERATE Trail, presented at ...
read more ↘ ACC.16, a trial designed to study a class of drugs called CETP inhibitors, intended to decrease risk of cardiovascular disease.
↖ read less

0 Comments